← Back to Search

Patient Activation Program + Text Messaging for Type 2 Diabetes

N/A

Recruiting

Led By Adesuwa Olomu, MD, MS

Research Sponsored by Michigan State University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients should be taking at least one prescribed medication for BP or cholesterol management

Patients aged >18 at participating Federally Qualified Health Care centers (FQHCs) with a diagnosis of Type 2 diabetes (T2DM) with HbA1c >8, with or without CVD

Timeline

Screening 3 weeks

Treatment Varies

Follow Up progression of risk over 12 months

Awards & highlights

Study Summary

This trial will test if a patient activation program combined with mobile text messaging reinforcement can improve medication adherence in patients with diabetes, compared to mobile texting alone.

Who is the study for?

This trial is for adults over 18 with Type 2 diabetes and HbA1c >8, who are taking medication for blood pressure or cholesterol. They must be able to consent, have a cell phone (provided if needed), and read/speak English at a grade 6 level. It excludes those planning to move away, with cognitive impairments or in another cellphone program.Check my eligibility

What is being tested?

The study tests the Office-GAP program plus mobile texting against mobile texting alone in improving medication adherence among diabetic patients. Office-GAP involves shared decision-making during visits; both groups receive usual care and texts encouraging adherence.See study design

What are the potential side effects?

Since this trial focuses on communication strategies rather than new medications, traditional side effects aren't expected. However, participants may experience increased engagement or changes in their routine due to more frequent communications.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am on medication for blood pressure or cholesterol.

Select...

I am over 18, have Type 2 diabetes with HbA1c over 8, and may or may not have heart disease.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ progression of risk over 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~progression of risk over 12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and progression of risk over 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in Medication Adherence

Change in Medication adherence

Secondary outcome measures

Change in CollaboRATE

Change in Patient activation measure

Change in UK Prospective Diabetes Study (UKPDS)

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Office Guidelines Applied to Practice (Office-GAP) + mobile phone text messagingExperimental Treatment1 Intervention

Participants receive Office Guidelines Applied to Practice (Office-GAP) + mobile phone text messaging for 12 months.

Group II: Mobile phone text messagingActive Control1 Intervention

Participants receive mobile phone text messaging alone for 12 months.

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Michigan State UniversityLead Sponsor

186 Previous Clinical Trials

601,729 Total Patients Enrolled

University of MichiganOTHER

1,800 Previous Clinical Trials

6,378,762 Total Patients Enrolled

Adesuwa Olomu, MD, MS4.54 ReviewsPrincipal Investigator - Michigan State University

Michigan State University

5Patient Review

She was very personable and caring. She listened to everything I had to say.

Media Library

Mobile text messaging Clinical Trial Eligibility Overview. Trial Name: NCT04874116 — N/A

Type 2 Diabetes Research Study Groups: Office Guidelines Applied to Practice (Office-GAP) + mobile phone text messaging, Mobile phone text messaging

Type 2 Diabetes Clinical Trial 2023: Mobile text messaging Highlights & Side Effects. Trial Name: NCT04874116 — N/A

Mobile text messaging 2023 Treatment Timeline for Medical Study. Trial Name: NCT04874116 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this investigation still open to new participants?

"The data on clinicaltrials.gov reveals that this research project is actively recruiting participants, having been first posted in May 2021 and most recently updated in August 2022."

Answered by AI

How many participants is the trial currently accommodating?

"Affirmative. According to clinicaltrials.gov, the recruitment of participants for this medical trial is still ongoing; it was first posted on May 26th 2021 and last amended on August 24th 2022. A total of 378 patients are needed at one site for enrollment in the study."

Answered by AI